Incidence of Head and Neck Glomus Tumors (Paragangliomas)
Head and neck paragangliomas are rare tumors with an estimated incidence of 1-30 per 100,000 per year, accounting for approximately 0.5% of all head and neck cancers and 0.03% of all cancers 1.
Epidemiologic Data
The incidence data shows important trends:
Recent increase in malignant cases: The age-adjusted incidence of malignant head and neck paragangliomas has increased by 56% from 2000 to 2019, rising from 0.096 to 0.150 per 1,000 2. This represents the most contemporary data available on incidence trends.
Overall prevalence: Head and neck paragangliomas comprise 65-70% of all paragangliomas 3. These tumors account for 0.6% of all head and neck cancers 3.
Autopsy findings: Undiagnosed paragangliomas are found in 0.05-0.1% of patients at autopsy 4, suggesting these tumors are underdiagnosed during life.
Distribution and Patterns
Anatomic distribution: Head and neck paragangliomas are localized primarily in the carotid body, tympanic cavity, or jugular foramen 1. Only 10% of all paragangliomas have extra-adrenal localization, with head and neck sites representing a subset of these 5.
Multifocal disease: Approximately 10% of patients present with multiple paragangliomas, but this increases dramatically to 35-50% in familial cases 6. The most common associations are bilateral carotid body tumors or carotid body tumors with tympanic-jugular glomus 6.
Clinical Context
Malignant potential: While the majority of head and neck paragangliomas are benign, 6-19% develop metastasis outside the tumor site 3. Patients with distant metastasis at diagnosis have significantly worse outcomes, with 5-year survival of only 11.8% 3.
Hereditary component: At least one-third of all pheochromocytomas and paragangliomas have disease-causing germline mutations, with the prevalence in mutation carriers approaching 50% 4. SDHD mutations are most prevalent in head and neck paragangliomas, though SDHB, SDHC, and SDHAF2 are also implicated 1.